Literature DB >> 2676668

The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus.

I R Jones1, D R Owens, S Luzio, S Williams, T M Hayes.   

Abstract

Considerable disagreement exists regarding the levels of immunoreactive glucose dependent insulinotropic polypeptide in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Glucose dependent insulinotropic polypeptide levels were therefore studied during oral glucose and mixed meal tolerance tests in normal subjects (n = 31) and newly presenting previously untreated patients with Type 2 diabetes mellitus (n = 68). The tests were performed in random order after overnight fasts and blood samples were taken at 30 min intervals for 4 h. During the oral glucose tolerance test plasma glucose dependent insulinotropic polypeptide levels increased in the normal subjects from a fasting value of 20 +/- 3 pmol/l to a peak of 68 +/- 5 pmol/l at 30 min and in the Type 2 diabetic patients from a similar fasting level of 27 +/- 3 pmol/l to a higher peak value of 104 +/- 6 pmol/l at 30 min (p less than 0.001). Glucose dependent insulinotropic polypeptide levels were significantly higher in the diabetic patients compared with the normal subjects from 30-90 min (p less than 0.01-0.001) following oral glucose. During the meal tolerance test glucose dependent insulinotropic polypeptide levels increased in the normal subjects from a pre-prandial value of 22 +/- 4 pmol/l to a peak of 93 +/- 6 pmol/l at 90 min and in the Type 2 diabetic patients from a similar basal level of 25 +/- 2 pmol/l to a higher peak of 133 +/- 7 pmol/l at 60 min. Glucose dependent insulinotropic polypeptide concentrations were significantly higher in Type 2 diabetic patients compared with the normal subjects at 30 min (p less than 0.001), 60 min (p less than 0.01) and from 210-240 min (p less than 0.05) during the meal tolerance test. The groups were subdivided on the basis of degree of obesity and glucose dependent insulinotropic polypeptide concentrations were still higher in the diabetic subgroups compared with the normal subjects matched for weight. Type 2 diabetes mellitus is associated with an exaggerated glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals which is independent of any effect of obesity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2676668     DOI: 10.1007/bf00274255

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  28 in total

Review 1.  Identification and actions of gastric inhibitory polypeptide.

Authors:  J C Brown; J R Dryburgh; S A Ross; J Dupré
Journal:  Recent Prog Horm Res       Date:  1975

Review 2.  The incretin concept today.

Authors:  W Creutzfeldt
Journal:  Diabetologia       Date:  1979-02       Impact factor: 10.122

3.  Stimulation of insulin secretion by gastric inhibitory polypeptide in man.

Authors:  J Dupre; S A Ross; D Watson; J C Brown
Journal:  J Clin Endocrinol Metab       Date:  1973-11       Impact factor: 5.958

4.  The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion.

Authors:  I R Jones; D R Owens; A J Moody; S D Luzio; T Morris; T M Hayes
Journal:  Diabetologia       Date:  1987-09       Impact factor: 10.122

5.  Effect of atropine on glucose-stimulated gastric inhibitory polypeptide.

Authors:  J N Larrimer; E L Mazzaferri; S Cataland; H S Mekhjian
Journal:  Diabetes       Date:  1978-06       Impact factor: 9.461

6.  Gastric inhibitory polypeptide release after oral glucose: relationship to glucose intolerance, diabetes mellitus, and obesity.

Authors:  M Salera; P Giacomoni; L Pironi; G Cornia; M Capelli; A Marini; F Benfenati; M Miglioli; L Barbara
Journal:  J Clin Endocrinol Metab       Date:  1982-08       Impact factor: 5.958

7.  Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus.

Authors:  S A Ross; J C Brown; J Dupré
Journal:  Diabetes       Date:  1977-06       Impact factor: 9.461

8.  Disparity between glucose-dependent insulinotropic polypeptide and insulin responses in obese man.

Authors:  D L Sarson; P G Kopelman; H S Besterman; T R Pilkington; S R Bloom
Journal:  Diabetologia       Date:  1983-11       Impact factor: 10.122

9.  The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera.

Authors:  T Krarup; J J Holst
Journal:  Regul Pept       Date:  1984-09

10.  Effect of pretreatment with a high fat diet on the gastric inhibitory polypeptide and insulin responses to oral triolein and glucose in rats.

Authors:  S M Hampton; P Kwasowski; K Tan; L M Morgan; V Marks
Journal:  Diabetologia       Date:  1983-04       Impact factor: 10.122

View more
  17 in total

Review 1.  The role of incretin therapy at different stages of diabetes.

Authors:  Simona Cernea
Journal:  Rev Diabet Stud       Date:  2011-11-10

Review 2.  Treatment of prediabetes.

Authors:  Mustafa Kanat; Ralph A DeFronzo; Muhammad A Abdul-Ghani
Journal:  World J Diabetes       Date:  2015-09-25

Review 3.  Incretins and the development of type 2 diabetes.

Authors:  Juris J Meier; Michael A Nauck
Journal:  Curr Diab Rep       Date:  2006-06       Impact factor: 4.810

Review 4.  Development of minimally invasive techniques for management of medically-complicated obesity.

Authors:  Farzin Rashti; Ekta Gupta; Suzan Ebrahimi; Timothy R Shope; Timothy R Koch; Christopher J Gostout
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

5.  Comparison of composite whole body insulin sensitivity index derived from mixed meal test and oral glucose tolerance test in insulin resistant obese subjects.

Authors:  Hadi Selimoglu; Cevdet Duran; Sinem Kiyici; Metin Guclu; Canan Ersoy; Guven Ozkaya; Erdinc Erturk; Ercan Tuncel; Sazi Imamoglu
Journal:  Endocrine       Date:  2009-07-14       Impact factor: 3.633

Review 6.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

7.  GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans.

Authors:  Sharmila C Subaran; Matthew A Sauder; Weidong Chai; Linda A Jahn; Dale E Fowler; Kevin W Aylor; Ananda Basu; Zhenqi Liu
Journal:  Clin Sci (Lond)       Date:  2014-08       Impact factor: 6.124

8.  Direct assessment of liver glycogen storage by 13C nuclear magnetic resonance spectroscopy and regulation of glucose homeostasis after a mixed meal in normal subjects.

Authors:  R Taylor; I Magnusson; D L Rothman; G W Cline; A Caumo; C Cobelli; G I Shulman
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

9.  WNT/beta-catenin increases the production of incretins by entero-endocrine cells.

Authors:  J M García-Martínez; A Chocarro-Calvo; C M Moya; C García-Jiménez
Journal:  Diabetologia       Date:  2009-07-07       Impact factor: 10.122

10.  Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes.

Authors:  Victor A Gault; Peter R Flatt; Clifford J Bailey; Patrick Harriott; Brett Greer; Mark H Mooney; Finbarr P M O'harte
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.